This is a non-randomised, open label, single site (Austin Hospital), dose cohort study of CS-1008 in patients with advanced colorectal carcinoma who have received at least one previous regimen of chemotherapy treatment for metastatic disease. Consenting, eligible patients will each receive a course of seven doses of CS-1008, given weekly as an intravenous (IV) infusion over 30 minutes. The initial infusion of CS-1008 is trace labeled with Indium-111 (111In-CS-1008). Ten to 25 patients will be treated in cohorts in which the allocated initial and sequential weekly doses of CS-1008 are assessed. Each of the five dose level cohorts will be made up of two patients and are expandable to five patients if additional information about biodistribution and/or pharmacokinetics of the cohort dose is required. The initial 111In-CS-1008 dose is followed by gamma camera imaging for biodistribution and tumour uptake studies and with blood sampling over a 10 day period to evaluate pharmacokinetics and serum biomarkers. Weekly infusions of CS-1008 will subsequently occur. The day 36 infusion of CS-1008 will also be trace labeled with 111In, with subsequent gamma camera imaging for biodistribution and tumour uptake and blood sampling for pharmacokinetics and serum apoptosis biomarkers. Patients are reassessed for disease status (by RECIST v1.1), serum tumour biomarkers (CEA - carcinoembryonic antigen) and for development of human-anti-CS-1008-antibody development (HAHA) between day 44-50 (end of cycle/study visit). Patients are assessed for changes in the tumour metabolism following CS-1008 administration with 18F-FDG PET/CT scans at baseline, day 15 and end of cycle one.